<DOC>
	<DOCNO>NCT01196559</DOCNO>
	<brief_summary>The purpose study evaluate objective response rate safety platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patient treat vinorelbine gemcitabine combination chemotherapy .</brief_summary>
	<brief_title>Vinorelbine Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer</brief_title>
	<detailed_description>Other objective study evaluate Progression-free survival measure CA-125 response rate .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Participants must sign approve informed consent form ( ICF ) Histologically cytologically confirm epithelial ovarian/fallopian tube/primary peritoneal carcinoma Patients receive frontline , platinum/taxane base chemotherapy regimen Patients progress whose best response recent platinumbased therapy less partial response classify platinumrefractory/resistant ovarian cancer progress within six month complete recent platinumbased chemotherapy Participants must receive prior platinumbased chemotherapy management primary disease must receive 3 prior systemic cytotoxic regimen . Patients least one bidimensionally measurable and/or evaluable ( unidimensionally measurable ) target lesion nonirradiated area increase Ca 125 A &gt; = 4 week interval last chemotherapy regimen start study treatment Age 2075 year old Performance status ( WHO ) 02 Life expectancy least three month Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9 gr/mm^3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2 mg/dl ) prior therapy vinorelbine gemcitabine treatment &gt; 2 cytotoxic regimen ( include primary platinum taxane chemotherapy ) Serious comorbidities ( determined investigator ) , limited , active congestive heart failure , recent myocardial infarction active infection . Concurrent malignancy require therapy ( exclude noninvasive carcinoma carcinoma situ ) . Symptomatic central nervous system ( CNS ) metastasis . Uncontrolled intestinal obstruction Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational Pregnant nursing .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>ovarian cancer</keyword>
</DOC>